Synvista Starts Study With Alagebrium for Chronic Heart Failure

Synvista Therapeutics has dosed the first patient in BENEFICIAL, a 100-patient Phase II trial of alagebrium in patients with chronic heart failure.

The double-blind, placebo-controlled, randomized study will measure the effect of alagebrium on exercise tolerance in patients.

Noah Berkowitz, Synvista’s president and CEO, said the study will involve nine months of treatment, and the company hopes to announce results in 2009.